Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

LGI1 and CASPR2 neurological autoimmunity in children
López‐Chiriboga, A. Sebastian , Ζεκερίδου, Αναστασία , McKeon, Andrew , Dubey, Divyanshu , Lennon, Vanda A. , Tillema, Jan‐Mendelt , Patterson, Marc C. , Gadoth, Avi , Aaen, J. Gregory, Brenton, J. Nicholas , Bui, Jonathan D. , Moen, Amanda, Otten, Catherine , Piquet, Amanda L. , Pittock, Sean J. , Pittock, S J , Brenton, J Nicholas , McKeon, Andrew , Dubey, Divyanshu , Patterson, Marc , Klein, Christopher J. , Flanagan, Eoin P. , Wirrell, Elaine

Mayo Clinic

Annals of Neurology | August 7, 2018 | Volume: 84 | Issue: 3 | Pages: 473-480

10.1002/ana.25310 | PMID 30076629 Get It

The clinical phenotype of leucine‐rich glioma‐inactivated protein 1 (LGI1) and contactin‐associated proteinlike 2 (CASPR2) autoimmunity is well defined in adults. Data for children are limited (<10 cases). Among 13,319 pediatric patients serologically tested for autoimmune neurological disorders (2010–2017), 264 were seropositive for voltage‐gated potassium channel‐complex–IgG (radioimmunoprecipitation). Only 13 (4.9%) were positive by transfected cell‐binding assay for LGI1‐IgG (n = 7), CASPR2‐IgG (n = 3), or both (n = 3). This is significantly less than in adults. Encephalopathy, seizures, and peripheral nerve hyperexcitability were common, as was coexisting autoimmunity. No faciobrachial dystonic seizures or cancers were identified. Functional neurologic disorders were frequently the initial diagnosis, and immunotherapy appeared beneficial. Ann Neurol 2018;84:473–480
The Volume-Outcome Relationship in Retroperitoneal Soft Tissue Sarcoma: Evidence of Improved Short- and Long-Term Outcomes at High-Volume Institutions
Bagaria, Sanjay P. , Neville, Matthew R., Gray, Richard J. , Gabriel, Emmanuel , Ashman, Jonathan B. , Attia, Steven , Wasif, Nabil , Neville, Matthew, Bagaria, Sanjay P , Gabriel, Emmanuel

Mayo Clinic

Sarcoma | July 24, 2018 | Volume: 2018 | Issue: No issue available | Pages: 1-10

10.1155/2018/3056562 | PMID 30140165 Get It

Background. We sought to study the association between RPS case volume and outcomes. Although a relationship has been demonstrated between case volume and patient outcomes in some cancers, such a relationship has not been established for retroperitoneal sarcomas (RPSs). Study Design. The National Cancer Database (NCDB) was queried for patients undergoing treatment for primary RPS diagnosed between 2004 and 2013. Mean annual patient volume for RPS resection was calculated for all hospitals and divided into low volume (<5 cases/year), medium volume (5–10 cases/year), and high volume (>10 cases/year). Risk-adjusted regression analyses were performed to identify predictors of 30-day surgical mortality, R0 margin status, and overall survival (OS). Results. Our study population consisted of 5,407 patients with a median age of 61 years, of whom 47% were male and 3,803 (70%) underwent surgical resection. Absolute 30-day surgical mortality and R0 margin rate following surgery for low-, medium-, and high-volume institutions were 2.4%, 1.3%, and 0.5% (p=0.027) and 68%, 65%, and 82%, (p<0.001), respectively. Five-year overall survival rates for low, medium, and high-volume institutions were 56%, 57%, and 66%, respectively (p<0.001). Patients treated at low-volume institutions had a significantly higher risk of 30-day mortality (adjusted OR = 4.66, 95% CI 2.26–9.63) and long-term mortality (adjusted HR = 1.56, 95% CI 1.16–2.11) compared to high-volume institutions. Conclusion. We demonstrate the existence of a hospital sarcoma service line volume-oncologic outcome relationship for RPS at the national level and provide benchmark data for cancer care delivery systems and policy makers.
Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer
Liu, Deli , Takhar, Mandeep, Alshalalfa, Mohammed , Erho, Nicholas , Shoag, Jonathan E. , Jenkins, Robert B. , Karnes, R. Jeffrey , Ross, Ashley E. , Schaeffer, Edward M. , Rubin, Mark A. , Klein, Eric A. , Tomlins, Scott A. , Spratt, Daniel E. , Spratt, Daniel E , Klein, Eric A , Trock, Bruce J , Den, Robert B. , Davicioni, Elai , Sboner, Andrea , Barbieri, Christopher , Rubin, Mark A

Mayo Clinic

JCO Precision Oncology | July 24, 2018 | Volume: No volume available | Issue: 2 | Pages: 1-13

10.1200/po.18.00036 | PMID 30761387 Get It

Purpose Molecular characterization of prostate cancer, including The Cancer Genome Atlas, has revealed distinct subtypes with underlying genomic alterations. One of these core subtypes, SPOP (speckle-type POZ protein) mutant prostate cancer, has previously only been identifiable via DNA sequencing, which has made the impact on prognosis and routinely used risk stratification parameters unclear. Methods We have developed a novel gene expression signature, classifier (Subclass Predictor Based on Transcriptional Data), and decision tree to predict the SPOP mutant subclass from RNA gene expression data and classify common prostate cancer molecular subtypes. We then validated and further interrogated the association of prostate cancer molecular subtypes with pathologic and clinical outcomes in retrospective and prospective cohorts of 8,158 patients. Results The subclass predictor based on transcriptional data model showed high sensitivity and specificity in multiple cohorts across both RNA sequencing and microarray gene expression platforms. We predicted approximately 8% to 9% of cases to be SPOP mutant from both retrospective and prospective cohorts. We found that the SPOP mutant subclass was associated with lower frequency of positive margins, extraprostatic extension, and seminal vesicle invasion at prostatectomy; however, SPOP mutant cancers were associated with higher pretreatment serum prostate-specific antigen (PSA). The association between SPOP mutant status and higher PSA level was validated in three independent cohorts. Despite high pretreatment PSA, the SPOP mutant subtype was associated with a favorable prognosis with improved metastasis-free survival, particularly in patients with high-risk preoperative PSA levels. Conclusion Using a novel gene expression model and a decision tree algorithm to define prostate cancer molecular subclasses, we found that the SPOP mutant subclass is associated with higher preoperative PSA, less adverse pathologic features, and favorable prognosis. These findings suggest a paradigm in which the interpretation of common risk stratification parameters, particularly PSA, may be influenced by the underlying molecular subtype of prostate cancer.
Discrepancies in Self-Reported and Actual Conflicts of Interest for Robotic Pediatric Urological Surgery
Jimbo, Masaya , Granberg, Candace F. , Osumah, Tijani , Bandari, Jathin , Cannon, Glenn M., Gargollo, Patricio C. , Osumah, Tijani S, Routh, Jonathan C.

Mayo Clinic

Journal of Urology | July 24, 2018 | Volume: 201 | Issue: 2 | Pages: 393-399

10.1016/j.juro.2018.07.043 | PMID 30053509 Get It

What is the role of apical ventriculotomy in children and young adults with hypertrophic cardiomyopathy?
Thompson, Alex , Dearani, Joseph A. , Johnson, Jonathan N. , Schaff, Hartzell V. , Towe, Eric, Palfreeman, Jared, Wackel, Philip L. , Cetta, Frank , Thompson, Alex J , Towe, Eric C, Schaff, Hartzell , Dearani, Joseph A.

Mayo Clinic

Congenital Heart Disease | July 19, 2018 | Volume: 13 | Issue: 4 | Pages: 617-623

10.1111/chd.12618 | PMID 30019505 Get It

A novel etiology for craniospinal hypovolemia: a case of inferior vena cava obstruction
Kumar, Neeraj , Neidert, Newton B. , Bjarnason, Haraldur , Diehn, Felix E. , Bjarnason, Haraldur , Campeau, Norbert G. , Morris, Jonathan M.

Mayo Clinic

Journal of Neurosurgery: Spine | July 13, 2018 | Volume: 29 | Issue: 4 | Pages: 452-455

10.3171/2018.2.spine171373 | PMID 30004315 Get It

The authors report on a patient with craniospinal hypovolemia and inferior vena cava obstruction, and describe how the two conditions may be linked. This unique report further advances the emerging literature on spinal CSF venous fistulae.
Mexiletine rescues a mixed biophysical phenotype of the cardiac sodium channel arising from the SCN5A mutation, N406K, found in LQT3 patients
Hu, Rou-Mu, Tester, David J. , Li, Ryan , Sun, Tianyu , Peterson, Blaise Z., Ackerman, Michael J. , Makielski, Jonathan C., Tan, Bi-Hua, Li, Ryan, Tan, Bi‐Hua

Mayo Clinic

Channels | July 7, 2018 | Volume: 12 | Issue: 1 | Pages: 176-186

10.1080/19336950.2018.1475794 | PMID 29983085 Get It